BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim BK, Kang WJ, Kim JK, Seong J, Park JY, Kim DY, Ahn SH, Lee DY, Lee KH, Lee JD, Han KH. 18F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. Cancer. 2011;117:4779-4787. [PMID: 21469082 DOI: 10.1002/cncr.26099] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Gonzalez-guindalini FD, Botelho MPF, Harmath CB, Sandrasegaran K, Miller FH, Salem R, Yaghmai V. Assessment of Liver Tumor Response to Therapy: Role of Quantitative Imaging. RadioGraphics 2013;33:1781-800. [DOI: 10.1148/rg.336135511] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 5.3] [Reference Citation Analysis]
2 Hayano K, Lee SH, Sahani DV. Imaging for assessment of treatment response in hepatocellular carcinoma: Current update. Indian J Radiol Imaging 2015;25:121-8. [PMID: 25969635 DOI: 10.4103/0971-3026.155835] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
3 Song MJ. Bae SH, Lee SW, Song DS, Kim HY, Yoo IeR, Choi JI, Lee YJ, Chun HJ, Lee HG, Choi JY, Yoon SK. 18F-fluorodeoxyglucose PET/CT predicts tumour progression after transarterial chemoembolization in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2013;40:865-873. [PMID: 23436073 DOI: 10.1007/s00259-013-2366-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
4 Park JH, Kim DH, Kim SH, Kim MY, Baik SK, Hong IS. The Clinical Implications of Liver Resection Margin Size in Patients with Hepatocellular Carcinoma in Terms of Positron Emission Tomography Positivity. World J Surg 2018;42:1514-22. [PMID: 29026966 DOI: 10.1007/s00268-017-4275-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
5 Talbot J, Michaud L, Grange J, Rosmorduc O, Balogova S. Use of choline PET for studying hepatocellular carcinoma. Clin Transl Imaging 2014;2:103-13. [DOI: 10.1007/s40336-014-0055-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
6 Ahn SY, Lee JM, Joo I, Lee ES, Lee SJ, Cheon GJ, Han JK, Choi BI. Prediction of microvascular invasion of hepatocellular carcinoma using gadoxetic acid-enhanced MR and (18)F-FDG PET/CT. Abdom Imaging. 2015;40:843-851. [PMID: 25253426 DOI: 10.1007/s00261-014-0256-0] [Cited by in Crossref: 61] [Cited by in F6Publishing: 60] [Article Influence: 8.7] [Reference Citation Analysis]
7 Horowitz JM, Kamel IR, Arif-tiwari H, Asrani SK, Hindman NM, Kaur H, Mcnamara MM, Noto RB, Qayyum A, Lalani T. ACR Appropriateness Criteria ® Chronic Liver Disease. Journal of the American College of Radiology 2017;14:S391-405. [DOI: 10.1016/j.jacr.2017.08.045] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
8 Tsai CL, Koong AC, Hsu FM, Graber M, Chen IS, Cheng JC. Biomarker studies on radiotherapy to hepatocellular carcinoma. Oncology 2013;84 Suppl 1:64-8. [PMID: 23428861 DOI: 10.1159/000345892] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
9 Kim DY, Lee HW, Kang W, Kim GM, Won JY, Yun M. Metabolic activity assessment by 18 F-fluorodeoxyglucose positron emission tomography in patients with hepatocellular carcinoma undergoing Yttrium-90 transarterial radioembolization. J Gastroenterol Hepatol 2021;36:1679-84. [PMID: 33226706 DOI: 10.1111/jgh.15357] [Reference Citation Analysis]
10 Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology 2014;273:30-50. [PMID: 25247563 DOI: 10.1148/radiol.14132362] [Cited by in Crossref: 256] [Cited by in F6Publishing: 208] [Article Influence: 36.6] [Reference Citation Analysis]
11 Rhee WJ, Hwang SH, Byun HK, Yun M, Han KH, Seong J. Risk stratification for locally advanced hepatocellular carcinoma using pretreatment alpha-foetoprotein and 18 F-fluoro-2-deoxyglucose positron emission tomography. Liver Int. 2017;37:592-599. [PMID: 27804192 DOI: 10.1111/liv.13297] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
12 Ohri N, Dawson LA, Krishnan S, Seong J, Cheng JC, Sarin SK, Kinkhabwala M, Ahmed MM, Vikram B, Coleman CN, Guha C. Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study. J Natl Cancer Inst. 2016;108. [PMID: 27377923 DOI: 10.1093/jnci/djw133] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
13 Gauthé M, Richard-Molard M, Cacheux W, Michel P, Jouve JL, Mitry E, Alberini JL, Lièvre A; Fédération Francophone de Cancérologie Digestive (FFCD). Role of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography in gastrointestinal cancers. Dig Liver Dis 2015;47:443-54. [PMID: 25766918 DOI: 10.1016/j.dld.2015.02.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
14 Lee S, Kim BK, Kim SU, Park Y, Chang S, Park JY, Kim do Y, Ahn SH, Chon CY, Han KH. Efficacy of sorafenib monotherapy versus sorafenib-based loco-regional treatments in advanced hepatocellular carcinoma. PLoS One. 2013;8:e77240. [PMID: 24155932 DOI: 10.1371/journal.pone.0077240] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
15 Liu GM, Xie WX, Zhang CY, Xu JW. Identification of a four-gene metabolic signature predicting overall survival for hepatocellular carcinoma. J Cell Physiol 2020;235:1624-36. [PMID: 31309563 DOI: 10.1002/jcp.29081] [Cited by in Crossref: 39] [Cited by in F6Publishing: 47] [Article Influence: 13.0] [Reference Citation Analysis]
16 Cho Y, Lee DH, Lee YB, Lee M, Yoo JJ, Choi WM, Cho YY, Paeng JC, Kang KW, Chung JK, Yu SJ, Lee JH, Yoon JH, Lee HS, Kim YJ. Does 18F-FDG positron emission tomography-computed tomography have a role in initial staging of hepatocellular carcinoma? PLoS One 2014;9:e105679. [PMID: 25153834 DOI: 10.1371/journal.pone.0105679] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
17 Song MJ, Bae SH, Yoo IR, Park CH, Jang JW, Chun HJ, Choi BG, Lee HG, Choi JY, Yoon SK. Predictive value of 18F-fluorodeoxyglucose PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma. World J Gastroenterol 2012; 18(25): 3215-3222 [PMID: 22783045 DOI: 10.3748/wjg.v18.i25.3215] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
18 Rani SD, Nemanich ST, Fettig N, Shoghi KI. Kinetic analysis of FDG in rat liver: effect of dietary intervention on arterial and portal vein input. Nucl Med Biol 2013;40:537-46. [PMID: 23454249 DOI: 10.1016/j.nucmedbio.2013.01.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
19 Lee SM, Kim HS, Lee S, Lee JW. Emerging role of 18F-fluorodeoxyglucose positron emission tomography for guiding management of hepatocellular carcinoma. World J Gastroenterol 2019; 25(11): 1289-1306 [PMID: 30918424 DOI: 10.3748/wjg.v25.i11.1289] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
20 She WH, Cheung TT, Yau TC, Chan AC, Chok KS, Chu FS, Liu RK, Poon RT, Chan SC, Fan ST, Lo CM. Survival analysis of transarterial radioembolization with yttrium-90 for hepatocellular carcinoma patients with HBV infection. Hepatobiliary Surg Nutr. 2014;3:185-193. [PMID: 25202695 DOI: 10.3978/j.issn.2304-3881.2014.07.09] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
21 Park JC, Lee JH, Cheoi K, Chung H, Yun MJ, Lee H, Shin SK, Lee SK, Lee YC. Predictive value of pretreatment metabolic activity measured by fluorodeoxyglucose positron emission tomography in patients with metastatic advanced gastric cancer: the maximal SUV of the stomach is a prognostic factor. Eur J Nucl Med Mol Imaging 2012;39:1107-16. [PMID: 22526958 DOI: 10.1007/s00259-012-2116-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
22 Simoneau E, Hassanain M, Madkhali A, Salman A, Nudo CG, Chaudhury P, Metrakos P. (18)F-Fluorodeoxyglucose positron-emission tomography could have a prognostic role in patients with advanced hepatocellular carcinoma. Curr Oncol. 2014;21:e551-e556. [PMID: 25089106 DOI: 10.3747/co.21.1959] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
23 Shao YY, Hsu CH, Cheng AL. Predictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we? Liver Cancer 2013;2:93-107. [PMID: 24159601 DOI: 10.1159/000343845] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
24 Donswijk ML, Hess S, Mulders T, Lam MG. [18F]Fluorodeoxyglucose PET/Computed Tomography in Gastrointestinal Malignancies. PET Clin 2014;9:421-41, v-vi. [PMID: 26050945 DOI: 10.1016/j.cpet.2014.07.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
25 Kim R, Lee JM, Shin CI, Lee ES, Yoon JH, Joo I, Kim SH, Hwang I, Han JK, Choi BI. Differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma on gadoxetic acid-enhanced liver MR imaging. Eur Radiol. 2016;26:1808-1817. [PMID: 26373763 DOI: 10.1007/s00330-015-4005-8] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 7.6] [Reference Citation Analysis]
26 Yoon H, Paeng JC, Kwak C, Park YH, Kim TM, Lee S, Chung J, Edmund Kim E, Lee DS. Prognostic implication of extrarenal metabolic tumor burden in advanced renal cell carcinoma treated with targeted therapy after nephrectomy. Ann Nucl Med 2013;27:748-55. [DOI: 10.1007/s12149-013-0742-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
27 Ezziddin S, Adler L, Sabet A, Pöppel TD, Grabellus F, Yüce A, Fischer H, Simon B, Höller T, Biersack H, Nagarajah J. Prognostic Stratification of Metastatic Gastroenteropancreatic Neuroendocrine Neoplasms by 18 F-FDG PET: Feasibility of a Metabolic Grading System. J Nucl Med 2014;55:1260-6. [DOI: 10.2967/jnumed.114.137166] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 5.6] [Reference Citation Analysis]
28 Kim TM, Paeng JC, Chun IK, Keam B, Jeon YK, Lee SH, Kim DW, Lee DS, Kim CW, Chung JK, Kim IH, Heo DS. Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma. Cancer 2013;119:1195-202. [PMID: 23212736 DOI: 10.1002/cncr.27855] [Cited by in Crossref: 103] [Cited by in F6Publishing: 93] [Article Influence: 10.3] [Reference Citation Analysis]
29 Ortega López N. PET/Computed Tomography in Evaluation of Transarterial Chemoembolization. PET Clin 2015;10:507-17. [PMID: 26384597 DOI: 10.1016/j.cpet.2015.05.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
30 Kim BK, Shim JH, Kim SU, Park JY, Kim DY, Ahn SH, Kim KM, Lim YS, Han KH, Lee HC. Risk prediction for patients with hepatocellular carcinoma undergoing chemoembolization: development of a prediction model. Liver Int. 2016;36:92-99. [PMID: 25950442 DOI: 10.1111/liv.12865] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 5.1] [Reference Citation Analysis]
31 Hwang SH, Lee M, Lee N, Park S, Kim CK, Park MA, Yun M. Increased 18F-FDG Uptake on PET/CT is Associated With Poor Arterial and Portal Perfusion on Multiphase CT. Clin Nucl Med 2016;41:296-301. [PMID: 26756099 DOI: 10.1097/RLU.0000000000001105] [Reference Citation Analysis]
32 Pimiento JM, Davis-Yadley AH, Kim RD, Chen DT, Eikman EA, Berman CG, Malafa MP. Metabolic Activity by 18F-FDG-PET/CT Is Prognostic for Stage I and II Pancreatic Cancer. Clin Nucl Med 2016;41:177-81. [PMID: 26673243 DOI: 10.1097/RLU.0000000000001098] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
33 Horowitz JM, Kamel IR, Arif-tiwari H, Asrani SK, Hindman NM, Kaur H, Mcnamara MM, Noto RB, Qayyum A, Lalani T. ACR Appropriateness Criteria ® Chronic Liver Disease. Journal of the American College of Radiology 2017;14:S103-17. [DOI: 10.1016/j.jacr.2017.02.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
34 Seo HJ, Kim GM, Kim JH, Kang WJ, Choi HJ. 18F-FDG PET/CT in hepatocellular carcinoma: detection of bone metastasis and prediction of prognosis. Nucl Med Commun. 2015;36:226-233. [PMID: 25460306 DOI: 10.1097/mnm.0000000000000246] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
35 Kornberg A, Friess H. 18F-fludeoxyglucose positron emission tomography for diagnosis of HCC: implications for therapeutic strategy in curative and non-curative approaches. Therap Adv Gastroenterol 2019;12:1756284819836205. [PMID: 30915167 DOI: 10.1177/1756284819836205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
36 Cui L, Xue H, Wen Z, Lu Z, Liu Y, Zhang Y. Prognostic roles of metabolic reprogramming-associated genes in patients with hepatocellular carcinoma. Aging (Albany NY) 2020;12:22199-219. [PMID: 33188160 DOI: 10.18632/aging.104122] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Lee JW, Oh JK, Chung YA, Na SJ, Hyun SH, Hong IK, Eo JS, Song BI, Kim TS, Kim do Y. Prognostic Significance of 18F-FDG Uptake in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization or Concurrent Chemoradiotherapy: A Multicenter Retrospective Cohort Study. J Nucl Med. 2016;57:509-516. [PMID: 26742711 DOI: 10.2967/jnumed.115.167338] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
38 Song J, Lee YN, Kim YS, Kim SG, Jin SJ, Park JM, Choi GS, Chung JC, Lee MH, Cho YH, Choi MH, Kim DC, Choi HJ, Moon JH, Lee SH, Jeong SW, Jang JY, Kim HS, Kim BS. Predictability of preoperative 18F-FDG PET for histopathological differentiation and early recurrence of primary malignant intrahepatic tumors. Nuclear Medicine Communications 2015;36:319-27. [DOI: 10.1097/mnm.0000000000000254] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
39 Kim MJ, Kim YS, Cho YH, Jang HY, Song JY, Lee SH, Jeong SW, Kim SG, Jang JY, Kim HS, Kim BS, Lee WH, Park JM, Lee JM, Lee MH, Choi DL. Use of (18)F-FDG PET to predict tumor progression and survival in patients with intermediate hepatocellular carcinoma treated by transarterial chemoembolization. Korean J Intern Med. 2015;30:308-315. [PMID: 25995661 DOI: 10.3904/kjim.2015.30.3.308] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
40 Pazo-Cid RA, Lanzuela M, Esquerdo G, Pérez-Gracia JL, Antón A, Amigo G, Trufero JM, García-Otín AL, Martín-Duque P. Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC). Clin Transl Oncol 2012;14:564-74. [PMID: 22855137 DOI: 10.1007/s12094-012-0842-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
41 Yeoh KW, Prawira A, Saad MZB, Lee KM, Lee EMH, Low GK, Mohd Nasir MHB, Phua JH, Chow WWL, Lim IJH, Omar YB, Ho RZW, Le TBU, Vu TC, Soo KC, Huynh H. Vinorelbine Augments Radiotherapy in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E872. [PMID: 32260169 DOI: 10.3390/cancers12040872] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Kim KA, Park MS, Ji HJ, Park JY, Han KH, Kim MJ, Kim KW. Diffusion and perfusion MRI prediction of progression-free survival in patients with hepatocellular carcinoma treated with concurrent chemoradiotherapy. J Magn Reson Imaging. 2014;39:286-292. [PMID: 24302545 DOI: 10.1002/jmri.24161] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
43 Sun DW, An L, Wei F, Mu L, Shi XJ, Wang CL, Zhao ZW, Li TF, Lv GY. Prognostic significance of parameters from pretreatment (18)F-FDG PET in hepatocellular carcinoma: a meta-analysis. Abdom Radiol (NY). 2016;41:33-41. [PMID: 26830609 DOI: 10.1007/s00261-015-0603-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
44 Lee SH, Hwang HK, Lee WJ, Yun M, Kang CM. Preoperative Metabolic Tumor Volume2.5 Associated with Early Systemic Metastasis in Resected Pancreatic Cancer: A Transcriptome-Wide Analysis. Gut Liver 2019;13:356-65. [PMID: 30602217 DOI: 10.5009/gnl18242] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]